Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)
China · Delayed Price · Currency is CNY 2.570
+0.020 (0.78%)
Feb 13, 2026, 3:04 PM CST
SHE:000518 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 334.25 | 195.87 | 229.61 | 261.99 | 344.49 | 501.61 |
Other Revenue | 7.65 | 7.65 | 5.81 | 8.16 | 6.47 | 3.79 |
| 341.9 | 203.52 | 235.42 | 270.15 | 350.96 | 505.4 | |
Revenue Growth (YoY) | 61.67% | -13.55% | -12.86% | -23.03% | -30.56% | 20.94% |
Cost of Revenue | 259.67 | 113.41 | 88.08 | 86.36 | 115.11 | 203.18 |
Gross Profit | 82.22 | 90.11 | 147.34 | 183.79 | 235.85 | 302.22 |
Selling, General & Admin | 115.64 | 127.33 | 182.46 | 187.13 | 211.48 | 213.96 |
Research & Development | 29.41 | 29.01 | 29.15 | 38.97 | 51.84 | 40.7 |
Other Operating Expenses | 1.4 | 1.42 | 1.37 | 2.08 | 2.2 | 2.1 |
Operating Expenses | 151.31 | 158.4 | 214.55 | 233.34 | 271.01 | 263.98 |
Operating Income | -69.08 | -68.29 | -67.21 | -49.56 | -35.16 | 38.24 |
Interest Expense | -2.38 | -2.12 | -2.46 | -0.72 | -0.7 | -0.78 |
Interest & Investment Income | 2.05 | 0.49 | 1.8 | 0.08 | 0.11 | 0.12 |
Currency Exchange Gain (Loss) | 0.05 | 0.05 | 0.08 | 0.32 | -0.03 | -0.27 |
Other Non Operating Income (Expenses) | 0.68 | 0.32 | -4.82 | -2.23 | -2.34 | -1.55 |
EBT Excluding Unusual Items | -68.69 | -69.55 | -72.62 | -52.11 | -38.11 | 35.76 |
Gain (Loss) on Sale of Investments | -0 | 0.04 | -0.02 | -0.26 | -0.54 | -0.03 |
Gain (Loss) on Sale of Assets | 3.24 | 2.41 | -0.02 | - | 0.21 | 0.55 |
Asset Writedown | -15.31 | -15.31 | -4 | -2.26 | - | -0.02 |
Legal Settlements | -8.26 | -8.26 | -2.85 | - | - | - |
Other Unusual Items | -23.25 | -23.05 | 0.09 | 1.03 | 2.42 | 0.18 |
Pretax Income | -112.28 | -113.73 | -79.43 | -53.61 | -36.04 | 36.44 |
Income Tax Expense | -0.51 | 0.07 | 0.99 | -0.33 | 2.24 | 8.78 |
Earnings From Continuing Operations | -111.77 | -113.81 | -80.41 | -53.28 | -38.27 | 27.66 |
Minority Interest in Earnings | 3.7 | 3.81 | 5.14 | 4.49 | 3.48 | -0.36 |
Net Income | -108.07 | -109.99 | -75.27 | -48.79 | -34.79 | 27.3 |
Net Income to Common | -108.07 | -109.99 | -75.27 | -48.79 | -34.79 | 27.3 |
Net Income Growth | - | - | - | - | - | 90.46% |
Shares Outstanding (Basic) | 1,032 | 1,030 | 1,030 | 1,029 | 1,029 | 1,030 |
Shares Outstanding (Diluted) | 1,032 | 1,030 | 1,030 | 1,029 | 1,029 | 1,030 |
Shares Change (YoY) | 0.20% | 0.02% | 0.03% | 0.01% | -0.07% | -0.10% |
EPS (Basic) | -0.10 | -0.11 | -0.07 | -0.05 | -0.03 | 0.03 |
EPS (Diluted) | -0.10 | -0.11 | -0.07 | -0.05 | -0.03 | 0.03 |
EPS Growth | - | - | - | - | - | 90.65% |
Free Cash Flow | 78.04 | -4.1 | -6.56 | -3.61 | -7.53 | 91.53 |
Free Cash Flow Per Share | 0.08 | -0.00 | -0.01 | -0.00 | -0.01 | 0.09 |
Gross Margin | 24.05% | 44.27% | 62.59% | 68.03% | 67.20% | 59.80% |
Operating Margin | -20.21% | -33.56% | -28.55% | -18.34% | -10.02% | 7.56% |
Profit Margin | -31.61% | -54.05% | -31.97% | -18.06% | -9.91% | 5.40% |
Free Cash Flow Margin | 22.82% | -2.01% | -2.79% | -1.34% | -2.15% | 18.11% |
EBITDA | -59.47 | -54.55 | -47.97 | -29.91 | -16.4 | 56.64 |
EBITDA Margin | -17.39% | -26.80% | -20.38% | -11.07% | -4.67% | 11.21% |
D&A For EBITDA | 9.62 | 13.74 | 19.25 | 19.64 | 18.76 | 18.4 |
EBIT | -69.08 | -68.29 | -67.21 | -49.56 | -35.16 | 38.24 |
EBIT Margin | -20.21% | -33.56% | -28.55% | -18.34% | -10.02% | 7.56% |
Effective Tax Rate | - | - | - | - | - | 24.10% |
Revenue as Reported | 341.9 | 203.52 | 235.42 | 270.15 | 350.96 | 505.4 |
Advertising Expenses | - | - | 0.18 | 116.01 | 135.3 | 125.05 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.